News

The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. It would expand Lonza’s US manufacturing presence from four to nine sites

The deal for the vaccine was awarded through the UK Health Security Agency. Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The

Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract. The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and

This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio. The combined company would operate as Pelthos Therapeutics and continue trading on the

Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US. A workforce of 45 members handles administration, quality control, and general

The privately held clinical-stage biotechnology company will also use the capital to progress its broader research pipeline in autoimmune disorders, immunology, neurology, and oncology. Juvia Group and Lightspeed

Under the deal, Rumi Therapeutics will develop the therapy, renaming it RTX-7340. Enthorin Therapeutics will receive an upfront sum, an option exercise fee, and milestone payments. The company

The initiative will support the acquisition and clinical advancement of ten to 15 drug programmes over the next three to five years. The company plans to source Phase

The regulatory status specifically includes rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), the indication for which the candidate is presently being evaluated. Orphan status is granted to support the